high dose group:Recombinant variant COVID-19 vaccine (Sf9 cell)

2 trials

Sponsors

Jiangsu Center for Disease Control and Prevention (Jiangsu Institute of Public Health)

Conditions

novel coronavirus pneumonia (COVID-19)

Phase 1

A phase I clinical trial of recombinant variant COVID-19 vaccine (Sf9 cell) (WSK-V102)

Active, not recruitingChiCTR2300069277

Jiangsu Center for Disease Control and Prevention (Jiangsu Institute of Public Health)novel coronavirus pneumonia (COVID-19)

Start: 2023-03-11Updated: 2023-05-29

Phase 2

A phase II clinical trial of recombinant variant COVID-19 vaccine (Sf9 cell) (WSK-V102)

Active, not recruitingChiCTR2300069278

Jiangsu Center for Disease Control and Prevention (Jiangsu Institute of Public Health)novel coronavirus pneumonia (COVID-19)

Start: 2023-03-11Updated: 2023-05-29